New drug AZD0305 takes on multiple myeloma in early trial
NCT ID NCT06106945
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study tests a new medicine called AZD0305 in people with multiple myeloma, a type of blood cancer. The trial has two phases: first, finding a safe dose, then seeing how well it works alone or with other cancer drugs. About 226 adults will take part. The goal is to control the disease, not cure it, as ongoing treatment may be needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
RECRUITINGDuarte, California, 91010, United States
-
Research Site
RECRUITINGIrvine, California, 92618, United States
-
Research Site
RECRUITINGAtlanta, Georgia, 30322, United States
-
Research Site
RECRUITINGBoston, Massachusetts, 02215, United States
-
Research Site
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
Research Site
WITHDRAWNSt Louis, Missouri, 63110, United States
-
Research Site
RECRUITINGNew York, New York, 10065, United States
-
Research Site
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Research Site
RECRUITINGFairfax, Virginia, 22031, United States
-
Research Site
RECRUITINGFitzroy, VIC3065, Australia
-
Research Site
RECRUITINGMelbourne, 3000, Australia
-
Research Site
RECRUITINGNedlands, 6009, Australia
-
Research Site
NOT_YET_RECRUITINGWollongong, 2500, Australia
-
Research Site
NOT_YET_RECRUITINGSalvador, 41253-190, Brazil
-
Research Site
NOT_YET_RECRUITINGSão Paulo, 04537-080, Brazil
-
Research Site
NOT_YET_RECRUITINGSão Paulo, 05652000, Brazil
-
Research Site
RECRUITINGHamilton, Ontario, L8V 5C2, Canada
-
Research Site
RECRUITINGOttawa, Ontario, K1H 8L6, Canada
-
Research Site
NOT_YET_RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
Research Site
RECRUITINGMontreal, Quebec, H4A 3J1, Canada
-
Research Site
NOT_YET_RECRUITINGNova Scotia, B3H 1V7, Canada
-
Research Site
RECRUITINGBeijing, 100044, China
-
Research Site
RECRUITINGChangsha, 410013, China
-
Research Site
RECRUITINGGuangzhou, 510060, China
-
Research Site
RECRUITINGShenyang, 110134, China
-
Research Site
RECRUITINGLille, 59037, France
-
Research Site
RECRUITINGNantes, 44000, France
-
Research Site
RECRUITINGEssen, 45147, Germany
-
Research Site
WITHDRAWNFreiburg im Breisgau, 79106, Germany
-
Research Site
RECRUITINGHamburg, 20246, Germany
-
Research Site
NOT_YET_RECRUITINGHeidelberg, 69120, Germany
-
Research Site
RECRUITINGLübeck, 23538, Germany
-
Research Site
RECRUITINGNuremberg, 90419, Germany
-
Research Site
NOT_YET_RECRUITINGTübingen, 72076, Germany
-
Research Site
RECRUITINGWürzburg, 97080, Germany
-
Research Site
RECRUITINGKashiwa, 277-8577, Japan
-
Research Site
RECRUITINGNagoya, 467-8602, Japan
-
Research Site
RECRUITINGYamagata, 990-9585, Japan
-
Research Site
NOT_YET_RECRUITINGBadalona, 8916, Spain
-
Research Site
RECRUITINGMadrid, 28027, Spain
-
Research Site
RECRUITINGMadrid, 28041, Spain
-
Research Site
RECRUITINGPamplona, 31005, Spain
-
Research Site
RECRUITINGSalamanca, 37007, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact